EUCTR2004-003885-14-ES进行中（未招募）1 期
Multidisciplinar, multicenter, randomized phase III clinical trial comparing taxotere plus estramustine phosphate plus prednisone, versus taxotere prednisone, in advanced prostate carcinoma patients with biochemical relapse during androgen ablation.
Aventis Pharma, S.A.0 个研究点目标入组 172 人开始时间: 2006年1月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 172
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Histologically confirmed prostate adenocarcinoma
- •- Confirmed prostate adenocarcinoma in biochemistry progression androgens block and demonstrated progression despite cessation of antiandrogen therapy.
- •- Patients must have received prior hormonal therapy.
- •- Castration levels of testosterone (Minor to 50 ng/dL)
- •- Biochemistry relapse.
- •- Adequate bone marrow, Hepatic and Renal function.
- •- Patients must be accessible for treatment and follow-up.
- •- Prior surgery and/or radiation therapy is allowed if at least 4 weeks have elapsed since the completion of radiation therapy and the patient have recovered from side effects.
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Prior cytotoxic chemotherapy (including AMP, Ketoconazole), radio isotopes or other hormonal therapy.
- •- Prior malignancy except any cancer adequately treated from wich the patient has been disease free for 2 years or more.
- •- Symptomatic peripheral neuropathy grade mayor or equal to 2 according to NCIC-CTG criteria.
- •- Concomitant serious illness or medical condition:
- •a) Uncontrolled or severe cardiovascular disease.
- •b) Active uncontrolled infection.
- •c) Active peptic ulcer.
- •d) Unstable diabetes mellitus.
- •- Previous history of tromboembolic events in the last 6 months or active thrombophlebitis.
- •- Medical contraindication for EMP including history to estradiol or nitrogen mustard.
研究者
相似试验
进行中（未招募）
不适用
Phase II, randomized, double arm, multi-center study evaluating the efficacy and safety of azithromycin for the long term prophylactic treatment of COPD in primary antibody deficiency patients with clinical and spirometrically confirmed COPD suffering from repeated acute exacerbationsprimary immunodefciency patients with COPD and frequent exacerbationsMedDRA version: 14.1Level: LLTClassification code 10029978Term: Obstructive chronic bronchitis with acute exacerbationSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10013289Term: Disorders involving the immune mechanismSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 14.1Level: LLTClassification code 10003554Term: Asthma aggravatedSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-004351-39-ITAZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
进行中（未招募）
不适用
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)EUCTR2009-012152-24-ITAbbott GmbH & Co. KG120
进行中（未招募）
不适用
Comparison of defined skin parameters in two comparable lesional skinareas after topical treatment with Soventol HydroCort 0.5 % Cremogel or Placebomanifest atopic dermatitis diagnosed according to Hanifin and Rajka, or seborrheic eczema or stasis dermatitisEUCTR2011-001175-38-DEMEDICE Arzneimittel Pütter GmbH & CO.KG
进行中（未招募）
1 期
A clinical trial of prostate cance aobut therapeutic immunotherapy strategiesmetastatic hormone-sensitive prostate cancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004377-13-ESSOGUG (Spanish Genitourinary Oncologic Group)120
Unknown
2 期
Safety, Tolerability andImmunogenicity of the candidate GEMCOVAC-19 (COVID-19vaccine) in healthy pediatric subjects of 5 to less than 18 yearsCTRI/2022/04/041880Gennova Biopharmaceuticals Limited